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Summary: Three-point mutations (R117H, N21I, A16V)
within the cationic trypsinogen gene have been identified in
patients with hereditary pancreatitis (HP). A genetic back-
ground has also been discussed for idiopathic juvenile chronic
pancreatitis (IJCP), which closely mimicks the clinical pattern
of HP, and alcoholic chronic pancreatitis because only a small
number of heavy drinkers develop pancreatitis. This prompted
us to screen 104 patients in our well-defined pancreatitis cohort
for the currently known cationic trypsinogen gene mutations.
The R117H mutation was detected in seven patients (six pa-
tients of two clinically classified HP families, one patient with
clinically classified IJCP) and the A16V mutation in one IJCP
patient. No cationic trypsinogen gene mutations were found in
the remaining 96 patients with chronic and recurrent acute pan-
creatitis of various etiologies. Our results demonstrate the need
for genetic testing to exclude HP, particularly in the presence of
an atypical or unknown family history. In addition, cationic
trypsinogen gene mutations are no predisposing factor in pa-
tients with chronic and recurrent acute pancreatitis of different
etiologies. Key Words: Cationic trypsinogen gene mutation—
Hereditary pancreatitis— Idiopathic juvenile chronic pancreati-
tis—Alcoholic chronic pancreatitis—Recurrent acute pancre-
atitis.
In industrialized countries, chronic pancreatitis (CP) is
caused by long-term alcohol abuse in approximately
70% of patients (1,2). Other causes of CP are rare (e.g.,
heredity, hyperlipidemia and hypercalcemia). In 10–30%
of cases, the cause of CP remains undetermined (1,2).
Irrespective of the etiology, the clinical pattern of CP is
characterized by an early stage with recurrent episodes of
acute pancreatitis (AP) followed by a late stage with
steatorrhea, diabetes mellitus, and pancreatic calcifica-
tions in most patients (2).
The pathogenesis of CP is unclear, and it is unknown
whether there are factors common to the etiologically
different forms of CP (3). It is assumed that autodiges-
tion secondary to intraglandular activation of trypsino-
gen is a primary event in AP. The underlying etiology-
specific mechanism remains unknown, however (3,4).
Hereditary pancreatitis (HP) offers the possibility to
study the pathophysiology of CP. HP is an autosomal
disorder with 80% penetrance and variable expressivity
(4). To date, in the CT gene, two-point mutations in exon
2 (N21I) and 3 (R117H), respectively, have been iden-
tified in several families with HP, suggesting a genetic
basis for the development of HP (4,5). Recently, a sec-
ond mutation in exon 2 (A16V) of the CT gene was
described in patients with both positive and negative
family history of CP (6).
At present, it is not clear whether CT gene mutations
are also found in nonhereditary CP (e.g., idiopathic CP
[ICP] and alcoholic CP [ACP]). Clinically, ICP com-
prises two subgroups: a juvenile type (IJCP), with an
average age at onset of approximately 25 years, and a
senile type (ISCP), with the first clinical manifestations
at the age of approximately 60 years. These two sub-
groups of ICP, first clinically characterized 20 years ago
and confirmed in a recent study at the Mayo Clinic (7),
appear to be two distinct entities with presumably dif-
ferent etiopathogeneses. IJCP closely mimicks the clini-
cal pattern of HP suggestive of a genetic basis, i.e., onset
Manuscript received February 24, 2000; revised manuscript accepted
May 12. 2000.
Address correspondence and reprint requests to Dr. H. E. Blum,
Department of Medicine II, University of Freiburg, Hugstetter-Strasse
55, D-79106 Freiburg, Germany. E-mail: heblum@ukl.uni-freiburg.de
Pancreas
Vol. 22, No. 1, pp. 18–23
© 2001 Lippincott Williams & Wilkins, Inc., Philadelphia
18
of recurrent AP in childhood or adolescence and progres-
sion to CP. In contrast to HP, there is no clinical evidence
of heredity in IJCP (7).
A genetic background for ACP has been postulated
based on (i) isolated reports of familial clustering (8), (ii)
recent studies on mutations of the cystic fibrosis gene in
a CP series of different etiologies, including ACP (9,10),
and (iii) the fact that only 5–10% of heavy drinkers de-
velop pancreatitis that may progress to ACP.
In most studies published to date, only patients of HP
families were investigated. The aim of the present study
was to determine the frequency of CT gene mutations in
our large series of clinically well-defined patients with
CP, including IJCP, HP, and ACP, and recurrent AP.
METHODS
Definitions
The diagnosis of CP was based on a typical history
and one or more of the following criteria: pancreatic
calcifications, typical histology, persistent exocrine in-
sufficiency, and/or pancreatic steatorrhea (fecal chymo-
trypsin test <120 g/g for at least 2 years, fecal fat >7
g/24 h). Data from each patient on the clinical history,
including onset of pancreatitis, etiology, hospitalization,
histopathology, and previous control studies were re-
viewed. Alcohol was considered causative in patients
with a daily intake of >80 g of ethanol for at least 5 years.
Alcohol consumption was documented by interviews of
the patient, family members, and social workers. Patients
with no or irregular minimal alcohol intake were classi-
fied as idiopathic after the exclusion of other rare causes
(e.g., heredity, hyperlipidemia, hypercalcemia, abdomi-
nal trauma, or previous radiation therapy). Follow-up is
defined as the time period from clinical onset, i.e., the
first episode of pancreatitis to the last consultation.
Patients
Between January 1 and December 31, 1998, an ethyl-
enediaminetetraacetic acid (EDTA) blood sample for
DNA analysis was obtained at the annual consultation
from all consecutive patients enrolled in our long-term
pancreatitis study (11). In addition, blood samples were
collected from members of HP families through their
family physician. All patients with HP and IJCP gave
informed consent to the DNA analysis.
The group with clinically classified HP comprised
three families (10 individuals tested). In one family (Ko),
two siblings and their deceased mother had CP. In a
second family (Da), previously described (12), four pa-
tients with calcified CP (IV/2, IV3, V/1, V/4) and two
asymptomatic individuals (V/2, V/3) were available for
analysis. The patient IV/1 and IV/4 have died from lung
and pancreatic cancer, respectively. In a third family
(Ta), two brothers had calcified CP; their father with
recurrent AP died at the age of 44 years from unknown
cause.
Clinical evidence of familial aggregation of CP was
noted in three families with proven ACP: (i) one family
with two brothers who had definite ACP (one has died);
(ii) a second family with two brothers with ACP and
their father who had a pancreatic pseudocyst, and (iii) a
third family with two brothers, one with calcified ACP,
one with recurrent abdominal pain suggestive of pancre-
atitis who committed suicide, and their deceased father
who had diabetes mellitus. Blood samples from each
patient (alive, with definite ACP) of the three families
were available for DNA analysis.
DNA analyses
EDTA blood samples were stored at 4°C before pro-
cessing at the Department of Internal Medicine II, Uni-
versity of Freiburg. DNA was purified from blood
samples using the QiaAmp Blood Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s recommenda-
tion. Exon 3 sequences of the CT gene were amplified
using polymerase chain reaction (PCR) primers 5-
GGTCCTGGGTCTCATACCTT-3 (forward) and 5-
GGGTAGGAGGCTTCACACTT-3 (reverse; amplifi-
cation conditions: initial 5-minute denaturation step at
94°C, followed by 30 cycles at 94°C for 30 seconds;
64°C for 30 seconds; 72°C for 1 minute, and a final
7-minute elongation step at 72°C). According to Whit-
comb et al. (5), as a consequence of the G to A change
in position 117, a novel restriction site for Afl III is
found. Therefore, the PCR products were digested with
Afl III overnight and analyzed by 1% agarose gel elec-
trophoresis. To detect the N21I mutation, the exon 2
sequences of the CT gene were amplified by seminested
PCR, using primers 5-CCCAAAATCTTGCATTT
GAC-3 (forward outer primer) and 5-ACA
GTTAGCAGAGGTAGAGTG-3 (reverse outer and in-
ner primer) for the first reaction (amplification condi-
tions: initial 5-minute denaturation step at 94°C, fol-
lowed by 20 cycles at 94°C for 30 seconds; 55°C for 30
seconds; 72°C for 2 minutes, and a final 7-minute elon-
gation step at 72°C) and 5-GCTGCCCCCTTTGAT
GATGAT-3 (forward inner primer) for the second am-
plification (amplification conditions: initial 5-minute de-
naturation step at 94°C, followed by 20 cycles at 94°C
for 30 seconds; 55°C for 30 seconds; 72°C for 30 sec-
onds, and a final 7-minute elongation step at 72°C). The
PCR product was purified with a PCR purification kit
according to the manufacturer’s recommendation (QIA-
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Quick PCR purification Kit; Qiagen). To detect the A to
T change in position 21 of exon 2, the purified PCR
fragment was sequenced using the forward inner primer
(Cycle Sequencing Kit; Amersham, Buckinghamshire,
England). A DNA sample from a patient with a known
N21I mutation was obtained from V. Keim (13) and
served as a positive control. To detect the A16V muta-
tion in exon 2, primers were designed as published by
Witt et al. (6): (5-CGCCACCCCTAACATGCTAT-3,
forward; 5-CTCTCCCAGGCAGACT GGCC-3 re-
verse; amplification conditions: the initial 5-minute de-
naturation step at 94°C, followed by 30 cycles at 94°C
for 30 seconds, 64°C for 30 seconds, 72°C for 30 sec-
onds, and a final 7-minute elongation step at 72°C). To
identify the loss of the restriction site for Fnu4HI owing
to the C to T change in codon 16, the PCR products were
digested overnight and analyzed with 1.5% agarose gel
electrophoresis.
Statistical analyses
Statistical analyses were performed to compare the
data of the three subgroups ACP, IJCP, and HP. All
analysis were done using the StatView 4.51 statistical
software package (Abacus Concepts, Berkley, CA).
Nominal data were analyzed using 2 test and Fisher’s
exact test when appropriate. p Values for pairwise com-
parisons were adjusted using the Bonferroni correction.
Continuous variables were analyzed using simple analy-
sis of variance followed by pairwise comparisons using
the Bonferroni-Dunn test and are presented as mean ±
standard deviation. A p value of <0.05 was considered
significant.
RESULTS
Clinical characteristics
A total of 104 patients (92 with CP, 12 with recurrent
AP) were enrolled in the present study. The clinical char-
acteristics of the patients are summarized in Table 1. The
two subgroups with HP and IJCP differ from the rest of
the cohort, especially ACP, with respect to gender dis-
tribution and the low mean age at clinical onset of dis-
ease. Pancreatic calcifications, exocrine insufficiency,
and diabetes mellitus are noted in a high percentage,
irrespective of the etiology. HP patients have a signifi-
cantly lower mean age at onset compared to IJCP pa-
tients. HP patients had the longest follow-up. A logistic
regression identified both the age and etiology as inde-
pendent factors for the incidence of diabetes mellitus.
Studies of the cationic trypsinogen gene
The results of the DNA analyses in the 104 patients are
shown in Table 2. Two asymptomatic members of the
HP family Da (V/2 and V/3, Fig. 1) and three (mother,
two siblings) and four (mother, father, two siblings)
asymptomatic family members of the two IJCP patients
who tested positive for the R117H and A16V mutation,
respectively (see below), were also tested.
In two families (Ko, Da) with clinical HP, the R117H
mutation was identified. All members with this mutation
had clinically documented CP except for a 20-year-old
women (V/2, Fig. 1). In a third family (Ta), no CT gene
mutation in exons 2 and 3 was found in two brothers with
definite CP.
In the cohort of nonalcoholic/nonhereditary CP, the
R117H mutation in the CT gene was detected in one
patient clinically classified as having IJCP. This family
(father, mother, and two siblings) had no exocrine insuf-
ficiency (fecal chymotrypsin test) in 1974. A re-
evaluation of the patients history with the help of several
family members revealed clinical evidence suggestive of
recurrent pancreatitis in some individuals of the maternal
kindred but no definite CP. DNA analysis of blood
samples from the mother and two siblings revealed no
R117H mutation. Because the patient’s father had died at
TABLE 1. Clinical characteristics of patients with chronic (CP) and recurrent acute pancreatitis (AP)
Etiology
No. of
pts
Sex
[m/f]
Age at onset
[years]*
Calcification
[No. of pts (%)]
Exocrine insufficiency
[No. of pts (%)]
Diabetes mellitus
[No. of pts (%)]
Follow-up
[years]*
Hereditary CP 8 4/4c 11.4 ± 5.9c 7 (88) 6 (75) 4 (50) 31.3 ± 14.4c
Alcoholic CP 58 55/3c 34.3 ± 7.0c 46 (79) 56 (97) 47 (81)c 20.7 ± 6.6
Non-alcoholic CP 26
idiopathic-juvenile 16 9/7b 21.1 ± 6.8ab 11 (69) 13 (81) 3 (19)b 19.0 ± 11.5a
idiopathic-senile 4 4/0 57.3 ± 7.1 4 (100) 4 (100) 2 (50) 18.0 ± 8.8
rare causes** 6 4/2 35.3 ± 15.8 4 (67) 5 (83) 3 (50) 20.3 ± 12.5
Recurrent AP*** 12 11/1 34.2 ± 17.0 0 (0) 0 (0) 2 (17) 20.2 ± 7.0
No. of pts: number of patients; CP, chronic pancreatitis; AP, acute pancreatitis; *: mean value ± SD; **: postradiation 2; hyperlipidemia 1,
hyperparathyreoidism 1, unknown 2; ***: biliary 4, alcoholic 4, idiopathic 2, hyperlipidemia 1, posttraumatic 1.
a p < 0.05 IJCP vs. HCP°.
b p < 0.05 IJCP vs. ACP°.
c p < 0.05 HCP vs. ACP°.
° after Bonferroni correction.
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the age of 60 years and no other available family mem-
bers were available for testing, the paternal kindred could
not be investigated. This patient’s 8-year-old son, how-
ever, has had recurrent abdominal pain since the age of 4
years and is positive for the R117H mutation. In another
patient clinically classified as having IJCP, the A16V
mutation was detected. This patient’s family has no his-
tory or clinical evidence of pancreatitis. DNA analysis
performed on both parents and one sibling revealed this
mutation in the patient’s mother and the sibling.
All remaining patients with CP caused by alcohol use
and rare causes or recurrent AP were negative for all
these mutation, including the patients with ACP associ-
ated with a suggestive family history.
DISCUSSION
The investigation of our large series of unselected con-
secutive CP patients was aimed at determining the preva-
lence of the currently known CT gene mutations in vari-
ous forms of CP. Compared to most previous studies
investigating affected members of HP families only, our
analysis included patients from our clinically well-
defined pancreatitis cohort followed for more than 30
years (11). The analysis was performed for the two
known mutations of the CT gene in HP families and the
recently described signal peptide cleavage site mutation
of this gene (4–6).
In our series, members of two of three clinically clas-
sified HP families revealed the R117H mutation,
whereas no mutation was detected in the third family.
These results confirm previous studies that suggest locus
heterogeneity but no racial specificity of CT gene muta-
tions in HP kindreds (4,13–15). In the study by Whit-
comb et al. (5) comprising 206 individuals from 25 fami-
lies with clinically symptomatic HP, 96 (47%) were
negative for both mutations, indicating that HP may be
associated with genes other than the CT gene. Indeed, in
a large family (J) in this study, HP was linked to a new
locus on chromosome 12 (16). All our HP patients, ex-
cept one with a documented mutation, had a typical his-
tory of recurrent pancreatitis and progression to definite
CP. One CT gene mutation–positive individual is still
asymptomatic at the age of 21 years, supporting the pre-
viously reported high but incomplete penetrance of the
trait (17,18). Furthermore, additional pathogenetic fac-
tors such as pregnancy may be important in HP (19).
IJCP is a subgroup of idiopathic CP. Despite no family
history of pancreatitis in patients with IJCP, the early
onset of recurrent pancreatitis suggests a possible genetic
defect (7,20). Of our 16 patients with IJCP, 14 were
negative for the three CT gene mutations. However, in
two patients, either a R117H or an A16V mutation was
detected, emphasizing the need for genetic testing to rule
out HP. In three unaffected family members (mother,
two siblings) of the patient positive for the R117H mu-
tation, this mutation was not found. The deceased father
was asymptomatic for pancreatic disease like other mem-
bers of this kindred. Thus, the mode of inheritance re-
mains unknown in this patient. A de novo R117H mu-
tation is possible. Interestingly, a review of this patient’s
family history revealed that his 8-year-old son has recur-
rent abdominal pain and is positive for the R117H mu-
tation. Unfortunately, no clinical tests for CP have been
done on this child because the father has so far refused
medical care for his son. In contrast to the high pen-
etrance of the R117H mutation, the A16V mutation was
detected in two asymptomatic first-degree relatives
(mother, brother) of our patient positive for this muta-
tion. In addition, there is no history of pancreatitis in
untested family members of the maternal kindred. Thus,
there must be a low penetrance of this mutation and other
(genetic) defects in this patient with IJCP.
No CT gene mutations were found in our patients with
CP of alcoholic, idiopathic-senile or rare type, or recur-
rent acute pancreatitis. In particular, genetic testing was
negative in two brothers with pancreatitis owing to fa-
milial hyperlipidemia and in four members with familial
clustering of ACP. Recently, evidence for a genetic link
between idiopathic or alcoholic CP and cystic fibrosis
(9,10,21,22) or 1-antitrypsin (1-AT) deficiency was
presented (23,24). The majority of these studies are
based on small series and preliminary analysis. These
results should be interpreted with caution because muta-
tions of the CFTR or 1-AT genes are common in the
general population in contrast to CT gene mutations. In
addition, the selection of patients is difficult because
there exists no standardized nomenclature for CP. Both
facts suggest a selection bias.
TABLE 2. Mutations in the cationic trypsinogen gene in
our cohort with chronic (CP) and recurrent acute
pancreatitis (AP)
No. of Pts
Mutation
Exon 3 Exon 2
R117H N21I A16V
Hereditary CP 8 6 0 0
Alcoholic CP 58 0 0 0
Non-alcoholic CP
idiopathic-juvenile 16 1 0 1
idiopathic-senile 4 0 0 0
rare causes* 6 0 0 0
Recurrent AP* 12 0 0 0
*: etiology as in Table 1.
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The results from our studies allow several major con-
clusions: Genetic testing is appropriate in patients with
ICP, particularly in the presence of an atypical or un-
known family history. The currently known CT gene
mutations are not predisposing genetic factor in patients
with ACP. Our results therefore support the concept that
different mechanisms and cofactors have to be consid-
ered in the pathogenesis of nonhereditary CP. Further-
more, in vitro and in vivo models are needed to define
the pathogenesis of HP in patients with CT gene muta-
tions. Further genetic analyses should identify novel
genes and mutations in patients with HP negative for the
known CT gene mutations. Finally, studies of patients
with well-defined CP of various etiologies are needed to
determine the relevance of CT gene mutations and to
identify cofactors responsible for the progression to CP.
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